Flu's deadly toll rises in Michigan as 2 kids die in Kent County, 1 in Macomb County
The deaths of three Michigan children from the flu were announced Thursday — bringing the grim tally statewide to five this year, state and local health officials told the Free Press.
Two of the most recent deaths occurred Kent County and the other was reported in Macomb County.
"I can confirm that there has been a pediatric flu-related death in Macomb County. We will not be releasing any further information on this unfortunate loss," said Andrew Cox, director/health officer of Macomb County Health and Community Services, in an emailed statement to the Free Press.
Neither the Michigan Department of Health and Human Services nor Cox would answer questions about when the child died, the age of the child, what strain of flu virus sickened the child, or whether the child had been hospitalized or received the seasonal flu vaccine.
In Kent County, Health Officer Dr. Adam London issued the following statement: 'We are deeply saddened by the loss of these young lives to influenza. This is a heartbreaking reminder that while the flu can be mild for some, it poses serious health risks for others. We encourage anyone who has not received a flu shot this season to consider doing so as soon as possible to protect our community and our children."
A spokesperson from Kent County did not immediately respond to a phone call or text message from the Free Press seeking information about when the children died, what type of flu virus they had, and whether they were vaccinated. Laina Stebbins, a spokesperson for the state health department, said only that they "are not sharing any further details."
The state health department reported the first two Michigan pediatric flu deaths of the season — in Wayne and Genesee counties — on Feb. 14 . Both of those children had the H1N1 type of influenza A, according to the state health department.
Their deaths come as flu activity surges in Michigan, putting pressure on hospital emergency departments. Corewell Health urged metro Detroiters earlier this month to carefully consider other options before seeking care at its hospitals, which have been strained by the rising number of people with flu, COVID-19 and RSV.
State influenza surveillance data shows that the spread of flu-like illnesses were at the highest level reportable — "very high" — in the week ending Feb. 15, with H1N1 and H3N2 types of influenza A causing the most infections.
In the last week alone, nearly 3,000 Michiganders were hospitalized with flu, according to the state dashboard. And among children, 9.7% of pediatric hospital emergency department visits were associated with flu, RSV or COVID-19 in the week ending Feb. 22. Of them, flu made up the lion's share, accounting for 7.9% of the hospital emergency visits among kids.
More: MDHHS: 2 Michigan children die from flu as hospitalizations climb
More: Michigan flu, RSV, COVID surges wreak 'havoc' in Corewell emergency departments
Statewide, seasonal flu vaccination rates are lower than they've been in the last several years. As of Feb. 22, just 24.7% of Michiganders had received the seasonal flu vaccine, according to the Michigan Seasonal Respiratory Viruses Dashboard.
When the first two Michigan children died, Dr. Natasha Bagdasarian, the state's chief medical executive, issued the following statement, reminding people that it's not too late to get the vaccine:
'We are heartbroken for the families who have experienced this loss. Last season, influenza claimed the lives of nearly 200 children across the United States. Influenza rates are currently very high, and if you did not receive a flu vaccine last fall, it is not too late to get one. It can still prevent the severe complications of influenza, including hospitalization and death.'
State health leaders recommend that everyone older than 6 months, including people who are pregnant, should get a seasonal flu vaccine. Additionally, when people get sick, it's important to get treatment early, they say, when antiviral medicine can limit the severity of illness and prevent dangerous complications.
Nationally, at least 86 children have died from flu so far this season, according to the U.S. Centers for Disease Control and Prevention.
There were eight pediatric flu deaths reported in Michigan during the 2023-24 season and eight in the 2022-23 season as well, Stebbins said.
(This story was updated with additional information.)
Contact Kristen Shamus: kshamus@freepress.com. Subscribe to the Detroit Free Press.
This article originally appeared on Detroit Free Press: Flu death toll rises to 5 in Michigan as 3 more children die
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Preliminary data shows opioid deaths dropping big in Michigan
GRAND RAPIDS, Mich. (WOOD) — The Michigan Department of Health and Human Services says its latest data shows opioid deaths continue to drop across the state. Nitrous oxide abuse up more than 500% in Michigan Provisional data from MDHHS says overdose deaths likely dropped by 34% from 2023 to 2024 — approximately 1,000 fewer lives lost. The agency called it 'continued progress' thanks to investments to combat oversdoses, both financially and in effort. Since 2019, Michigan Attorney General Dana Nessel's office has worked to secure more than from several drug manufacturers and retailers, providing funds for state treatment, recovery and prevention programs. 'The progress we are seeing in combatting the opioid epidemic proves what is possible when real investments are made in treatment and prevention,' Nessel . 'My office will continue working to hold those responsible for this crisis accountable to ensure the health and well-being of residents are put ahead of corporate greed.' 'You can do it': Woman who beat addiction aims to inspire others According to MDHHS, more than 1.3 million naloxone kits have been purchased and distributed, and nearly 34,000 have reportedly been used to reverse overdoses and save lives. Michigan's , which is powered primarily by opioids, has steadily climbed from 2000 to 2021. The MDHHS notes a rise in opioid prescriptions starting in 2000, a rise in heroin use starting in 2010 and the emergence of fentanyl in 2013. In Michigan, overdose deaths took a sharp rise in 2013, from 1,300 to 1,535. By 2017, the number was up to 2,686. Numbers dropped before another surge sparked in 2019, going from 2,354 to 3,096 in 2021. Since then, deaths have trended down. The state recorded 2,998 in 2022 and 2,931. The preliminary data recorded just 1,045 deaths from January through June of 2024, on track for roughly 2,100 for the year. Sign up for the News 8 daily newsletter Lauren Rousseau, the president of the Northwest Wayne County Chapter of Face Addiction Now, says there is still a lot of work to do. 'White overdose deaths have declined significantly, due in part to the increased accessibility of Narcan, nonfatal overdoses remain high,' Rousseau said in a statement. 'Sustained funding, community engagement and a continued focus on reducing stigma are essential to turning the tide on the opioid crisis for good.' Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.


Business Upturn
3 days ago
- Business Upturn
LEX Diagnostics Submits Dual Applications for FDA 510(k) Clearance and CLIA Waiver for Groundbreaking LEX VELO System
CAMBRIDGESHIRE, United Kingdom, June 06, 2025 (GLOBE NEWSWIRE) — LEX Diagnostics, a leading innovator in molecular diagnostics, has submitted dual applications to the U.S. Food and Drug Administration (FDA) seeking 510(k) clearance and CLIA waived status for its VELO system, an ultra-fast point-of-care molecular diagnostics platform designed to deliver highly sensitive PCR results for key respiratory pathogens directly from a swab sample in under ten minutes.1 The FDA submission represents a pivotal step in LEX Diagnostics' strategy and underscores the company's commitment to advancing point-of-care testing with accurate, timely, and clinically actionable results. 'This milestone reflects the strength of our R&D and clinical validation programs, as well as our broader mission to make molecular diagnostics faster, simpler, and more accessible,' said Ed Farrell, Chief Executive Officer of LEX Diagnostics. 'We believe the LEX VELO system will redefine point-of-care testing by equipping healthcare providers with lab-quality results in minutes, enabling faster clinical decisions and improved patient outcomes without compromising quality while improving workflow—an achievement that will set us apart in the marketplace.' The LEX system supports multiplex testing for key respiratory pathogens, including Influenza A, Influenza B, and COVID-19, and is engineered to deliver PCR results in six to ten minutes, easily integrating into clinical workflows across primary care settings, urgent care clinics, pharmacies, physician office laboratories and decentralized acute settings. Its proprietary cartridge-based design eliminates the need for external liquid handling, promoting ease of use and reliability. LEX recently completed clinical studies in the United States with the VELO system and the Influenza/Covid assay during the 2024/2025 respiratory season. LEX Diagnostics anticipates U.S. market clearance in late 2025 or early 2026, in alignment with expected FDA review timelines. About Lex Diagnostics LEX Diagnostics, a TTP Group Company, is a molecular diagnostics company transforming point-of-care testing through its proprietary ultra-fast thermal cycling technology. Designed to deliver lab-quality PCR results directly from a swab sample in minutes, the VELO system bridges the gap between accuracy and accessibility, empowering healthcare professionals to make informed clinical decisions faster. LEX Diagnostics is headquartered in Cambridgeshire, United Kingdom. Learn more at and follow us on LinkedIn. Forward-Looking Statements This press release contains forward-looking statements, including but not limited to, statements regarding product development, regulatory timelines, market potential, and expected outcomes. These statements are based on current assumptions and expectations that are subject to risks, uncertainties, and changes in circumstances. Actual results may differ materially from those expressed or implied in forward-looking statements due to a variety of factors, including regulatory decisions, market conditions, and operational challenges. LEX Diagnostics undertakes no obligation to update or revise any forward-looking statements made herein, except as required by law. Media Contacts LEX Diagnostics Chris Hole [email protected] Scius Communications Katja Stout+44 778 943 5990 [email protected]
Yahoo
3 days ago
- Yahoo
LEX Diagnostics Submits Dual Applications for FDA 510(k) Clearance and CLIA Waiver for Groundbreaking LEX VELO System
CAMBRIDGESHIRE, United Kingdom, June 06, 2025 (GLOBE NEWSWIRE) -- LEX Diagnostics, a leading innovator in molecular diagnostics, has submitted dual applications to the U.S. Food and Drug Administration (FDA) seeking 510(k) clearance and CLIA waived status for its VELO system, an ultra-fast point-of-care molecular diagnostics platform designed to deliver highly sensitive PCR results for key respiratory pathogens directly from a swab sample in under ten minutes.1 The FDA submission represents a pivotal step in LEX Diagnostics' strategy and underscores the company's commitment to advancing point-of-care testing with accurate, timely, and clinically actionable results. 'This milestone reflects the strength of our R&D and clinical validation programs, as well as our broader mission to make molecular diagnostics faster, simpler, and more accessible,' said Ed Farrell, Chief Executive Officer of LEX Diagnostics. 'We believe the LEX VELO system will redefine point-of-care testing by equipping healthcare providers with lab-quality results in minutes, enabling faster clinical decisions and improved patient outcomes without compromising quality while improving workflow—an achievement that will set us apart in the marketplace.' The LEX system supports multiplex testing for key respiratory pathogens, including Influenza A, Influenza B, and COVID-19, and is engineered to deliver PCR results in six to ten minutes, easily integrating into clinical workflows across primary care settings, urgent care clinics, pharmacies, physician office laboratories and decentralized acute settings. Its proprietary cartridge-based design eliminates the need for external liquid handling, promoting ease of use and reliability. LEX recently completed clinical studies in the United States with the VELO system and the Influenza/Covid assay during the 2024/2025 respiratory season. LEX Diagnostics anticipates U.S. market clearance in late 2025 or early 2026, in alignment with expected FDA review timelines. About Lex Diagnostics LEX Diagnostics, a TTP Group Company, is a molecular diagnostics company transforming point-of-care testing through its proprietary ultra-fast thermal cycling technology. Designed to deliver lab-quality PCR results directly from a swab sample in minutes, the VELO system bridges the gap between accuracy and accessibility, empowering healthcare professionals to make informed clinical decisions faster. LEX Diagnostics is headquartered in Cambridgeshire, United Kingdom. Learn more at and follow us on LinkedIn. Forward-Looking Statements This press release contains forward-looking statements, including but not limited to, statements regarding product development, regulatory timelines, market potential, and expected outcomes. These statements are based on current assumptions and expectations that are subject to risks, uncertainties, and changes in circumstances. Actual results may differ materially from those expressed or implied in forward-looking statements due to a variety of factors, including regulatory decisions, market conditions, and operational challenges. LEX Diagnostics undertakes no obligation to update or revise any forward-looking statements made herein, except as required by law. Media Contacts LEX DiagnosticsChris Holeenquires@ Scius CommunicationsKatja Stout+44 778 943 5990katja@ Daniel Gooch+44 774 787 5479daniel@ _____________________1 This LEX Diagnostics product is currently under development and has not been cleared or approved by the U.S. Food and Drug Administration or any other regulatory authority. It is not available for sale or distribution in the U.S., the U.K. or any other jurisdiction. All product descriptions, data, or discussions are preliminary, subject to change, and do not represent final or FDA-approved claims, indications, or labeling.